Inhibiting FASN in cell lines of several breast cancer subtypes have effectively re-sensitized the cells to treatment with conventional chemotherapies paclitaxel (Menendez et al., 2005b), Adriamycin (Liu et al., 2008), 5-FU (Vazquez-Martin et al., 2007b), and vinorelbine (Menendez et al., 2004c). The gene discussed is FASN; the disease is breast cancer.